Takeshi Soeki Selected Research

Scarlet Red (Sudan IV)

6/2021	Inhibition of S1P Receptor 2 Attenuates Endothelial Dysfunction and Inhibits Atherogenesis in Apolipoprotein E-Deficient Mice.
11/2019	Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takeshi Soeki Research Topics

Disease

16	Atherosclerosis 11/2021 - 01/2004
15	Inflammation (Inflammations) 11/2021 - 02/2010
11	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 10/2002
10	Hypertension (High Blood Pressure) 12/2019 - 01/2004
8	Atherosclerotic Plaque (Atheroma) 11/2019 - 09/2011
8	Myocardial Infarction 01/2019 - 11/2002
7	Heart Failure 01/2021 - 12/2002
7	Insulin Resistance 01/2021 - 02/2010
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 10/2002
5	Body Weight (Weight, Body) 12/2021 - 06/2005
5	Diabetes Mellitus 01/2021 - 01/2004
5	Fibrosis (Cirrhosis) 01/2021 - 06/2005
5	Acute Coronary Syndrome 03/2019 - 08/2003
5	Type 2 Diabetes Mellitus (MODY) 01/2018 - 01/2013
5	Obesity 01/2016 - 11/2012
4	Atrial Fibrillation 01/2022 - 04/2010
4	Neoplasms (Cancer) 11/2021 - 07/2016
4	Thrombosis (Thrombus) 07/2020 - 12/2011
4	Ischemia 01/2018 - 12/2009
3	Dyslipidemias (Dyslipidemia) 01/2021 - 12/2014
3	Essential Hypertension 01/2015 - 01/2009
3	Ventricular Remodeling 12/2014 - 11/2002
3	Stable Angina 12/2011 - 08/2003
2	Venous Thromboembolism 07/2022 - 01/2018
2	Cardiac Arrhythmias (Arrythmia) 01/2021 - 01/2017
2	Proteinuria 01/2020 - 11/2012
2	Vascular System Injuries 02/2018 - 01/2013
2	Coronary Stenosis (Coronary Artery Stenosis) 10/2015 - 01/2004
2	Sarcoidosis (Schaumann Disease) 06/2015 - 01/2011
2	Myocardial Ischemia (Ischemic Heart Diseases) 11/2013 - 01/2012
2	Ventricular Tachycardia 11/2013 - 01/2011
2	Myocarditis (Carditis) 01/2013 - 01/2013
2	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2013 - 12/2009
2	Hypertrophy 04/2010 - 05/2004

Drug/Important Bio-Agent (IBA)

11	LipidsIBA 11/2021 - 01/2004
10	ApolipoproteinsIBA 11/2021 - 04/2016
10	Apolipoproteins E (ApoE)IBA 11/2021 - 10/2015
7	Docosahexaenoic AcidsIBA 03/2019 - 12/2014
7	Eicosapentaenoic AcidIBA 03/2019 - 12/2014
5	AnticoagulantsIBA 07/2022 - 06/2013
5	Angiotensin IIIBA 01/2021 - 12/2002
5	Factor Xa (Coagulation Factor Xa)IBA 01/2021 - 10/2015
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2015
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2019 - 04/2010
4	RivaroxabanIBA 07/2022 - 10/2015
4	DNA (Deoxyribonucleic Acid)IBA 11/2021 - 05/2004
4	CollagenIBA 10/2018 - 06/2005
4	C-Reactive ProteinIBA 01/2017 - 10/2002
4	Proteins (Proteins, Gene)FDA Link 05/2015 - 05/2004
4	LDL CholesterolIBA 01/2015 - 02/2010
4	Telmisartan (Micardis)FDA Link 01/2014 - 01/2009
3	Triglycerides (Triacylglycerol)IBA 12/2021 - 06/2011
3	HDL CholesterolIBA 12/2021 - 05/2013
3	Dipeptidyl-Peptidase IV InhibitorsIBA 11/2019 - 08/2015
3	Toll-Like Receptor 9IBA 01/2019 - 01/2016
3	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 01/2013
3	SodiumIBA 01/2018 - 07/2016
3	CreatinineIBA 01/2017 - 06/2011
3	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2017 - 12/2014
3	Blood Glucose (Blood Sugar)IBA 01/2017 - 04/2016
3	Arachidonic Acid (Vitamin F)IBA 12/2015 - 12/2014
3	GhrelinIBA 12/2014 - 01/2008
3	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 01/2014 - 01/2009
3	ThromboxanesIBA 01/2013 - 12/2009
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2013 - 11/2002
3	ONO 1301IBA 01/2013 - 12/2009
3	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2013 - 12/2009
2	edoxabanIBA 07/2022 - 01/2018
2	InterferonsIBA 11/2021 - 05/2015
2	Phosphotransferases (Kinase)IBA 11/2021 - 05/2004
2	Scarlet Red (Sudan IV)IBA 06/2021 - 11/2019
2	CanagliflozinIBA 11/2020 - 01/2017
2	RNA (Ribonucleic Acid)IBA 05/2020 - 01/2019
2	cilnidipineIBA 01/2020 - 11/2012
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2019 - 07/2016
2	Cell-Free Nucleic AcidsIBA 01/2018 - 01/2016
2	SymportersIBA 01/2018 - 01/2017
2	Indicators and Reagents (Reagents)IBA 01/2017 - 09/2011
2	Natriuretic PeptidesIBA 01/2017 - 06/2005
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 11/2016 - 12/2014
2	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 11/2016 - 12/2014
2	InflammasomesIBA 07/2016 - 10/2015
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 10/2015 - 08/2015
2	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2015 - 01/2011
2	Amlodipine (Norvasc)FDA LinkGeneric 01/2015 - 11/2012
2	AlbuminsIBA 01/2015 - 02/2010
2	MicroRNAs (MicroRNA)IBA 01/2015 - 01/2014
2	Angiotensin II Type 1 Receptor BlockersIBA 01/2014 - 11/2012
2	oxidized low density lipoproteinIBA 01/2014 - 02/2010
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2013 - 02/2010
2	AdipokinesIBA 05/2013 - 01/2013
2	Pharmaceutical PreparationsIBA 01/2013 - 01/2011
2	GadoliniumIBA 01/2013 - 01/2011
2	pitavastatin (itavastatin)FDA Link 06/2011 - 04/2010
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2009 - 11/2002

Therapy/Procedure

7	Therapeutics 07/2020 - 01/2011
4	Stents 03/2019 - 07/2011
4	Cardiac Rehabilitation 10/2018 - 01/2014
2	Catheter Ablation 01/2022 - 01/2011
2	Percutaneous Coronary Intervention 11/2021 - 01/2015